Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients

Visentin, Andrea; Imbergamo, Silvia; Gurrieri, Carmela; Frezzato, Federica; Trimarco, Valentina; Martini, Veronica; Severin, Filippo; Raggi, Flavia; Scomazzon, Edoardo; Facco, Monica; Semenzato, Gianpietro; Trentin, Livio

doi:10.1016/j.ejca.2016.11.020

Cited by 34 publications

(41 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CLL/SLL has an estimated incidence of 4 to 5 new cases/100 000 people/year and a median age at diagnosis of 72 years. It is characterized by a heterogeneous clinical course ranging from mild indolent to rapidly progressing diseases with shorter survival . Biological features are associated with the different clinical expression of CLL/SLL: in the indolent cases, no genetic abnormalities in the tumor suppressor gene TP53 and no mutated immunoglobulin heavy‐chain gene are usually found, whereas in the aggressive cases, TP53 gene abnormalities and/or complex karyotypes are typically detected .…”

Section: Neuropathies In Low‐grade Nhlmentioning

confidence: 99%

“…10 characterized by a heterogeneous clinical course ranging from mild indolent to rapidly progressing diseases with shorter survival. 12,13 Biological features are associated with the different clinical expression of CLL/SLL: in the indolent cases, no genetic abnormalities in the tumor suppressor gene TP53 and no mutated immunoglobulin heavy-chain gene are usually found, whereas in the aggressive cases, TP53 gene abnormalities and/or complex karyotypes are typically detected. 12,14 Common etiologies of neuropathy in CLL are viral (varicella zoster virus, VZV; hepatitis C virus, HCV), iatrogenic (ibrutinib, lenalidomide), immune-mediated, idiopathic, rarely due to peripheral nerve invasion by leukemic cells 15,16 or light chain amyloidosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Peripheral nervous system involvement in lymphomas

Briani

Visentin

Campagnolo

et al. 2019

J Peripheral Nervous Sys

Self Cite

View full text Add to dashboard Cite

The peripheral nervous system may be involved at any stage in the course of lymphoproliferative diseases. The different underlying mechanisms include neurotoxicity secondary to chemotherapy, direct nerve infiltration (neurolymphomatosis), infections, immune‐mediated, paraneoplastic or metabolic processes and nutritional deficiencies. Accordingly, the clinical features are heterogeneous and depend on the localization of the damage (ganglia, roots, plexi, and peripheral nerves) and on the involved structures (myelin, axon, and cell body). Some clinical findings, such a focal or diffuse involvement, symmetric or asymmetric pattern, presence of pain may point to the correct diagnosis. Besides a thorough medical history and neurological examination, neurophysiological studies, cerebrospinal fluid analysis, nerve biopsy (in selected patients with suspected lymphomatous infiltration) and neuroimaging techniques (magnetic resonance neurography and nerve ultrasound) may be crucial for a proper diagnostic workup.

show abstract

Section: Neuropathies In Low‐grade Nhlmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Peripheral nervous system involvement in lymphomas

Briani

Visentin

Campagnolo

et al. 2019

J Peripheral Nervous Sys

Self Cite

View full text Add to dashboard Cite

show abstract

“…Richter syndrome (RS) is the transformation of chronic lymphocytic leukaemia (CLL) into an aggressive lymphoma, most commonly diffuse large B cell lymphoma (DLBCL) (Visentin et al , , ; Mauro et al , ). Anthracycline‐ or platinum‐based regimes provide complete response (CR) rates of 20–30% in patients with a median survival of 8 months; there are currently no standard salvage approaches for RS (Vitale & Ferrajoli 2016: see Appendix S1).…”

Section: Clinical and Biological Characteristics Of Patientsmentioning

confidence: 99%

BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome

et al. 2018

Self Cite

View full text Add to dashboard Cite

“…BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome Richter syndrome (RS) is the transformation of chronic lymphocytic leukaemia (CLL) into an aggressive lymphoma, most commonly diffuse large B cell lymphoma (DLBCL) (Visentin et al, 2015(Visentin et al, , 2017Mauro et al, 2017). Anthracycline-or platinum-based regimes provide complete response (CR) rates of 20-30% in patients with a median survival of 8 months; there are currently no standard salvage approaches for RS (Vitale & Ferrajoli 2016: see Appendix S1).…”

mentioning

confidence: 99%